Sava Infond d.o.o. Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Sava Infond d.o.o. purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,500 shares of the company’s stock, valued at approximately $94,000.

A number of other large investors also recently bought and sold shares of the business. Victory Capital Management Inc. increased its stake in TransMedics Group by 11.3% in the third quarter. Victory Capital Management Inc. now owns 4,569 shares of the company’s stock worth $717,000 after purchasing an additional 464 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares during the last quarter. Bank of Montreal Can increased its stake in TransMedics Group by 1.2% in the 3rd quarter. Bank of Montreal Can now owns 69,973 shares of the company’s stock worth $11,136,000 after buying an additional 809 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in TransMedics Group by 3.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 18,473 shares of the company’s stock valued at $2,900,000 after buying an additional 657 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in TransMedics Group by 601.9% in the 3rd quarter. Quantbot Technologies LP now owns 19,738 shares of the company’s stock valued at $3,099,000 after buying an additional 16,926 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of research reports. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Robert W. Baird lowered their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group restated a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Up 0.2 %

NASDAQ:TMDX opened at $70.44 on Friday. The company’s 50-day simple moving average is $68.88 and its 200-day simple moving average is $88.90. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a market capitalization of $2.37 billion, a P/E ratio of 74.94 and a beta of 2.12.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.